https://www.PR.com/ Latest news releases from PR.com for Microvascular Therapeutics, Inc. Sun, 19 Jul 2026 15:01:25 -0400 © 2026 PR.com 60 en-us https://www.PR.com/images/logo_white.jpg https://www.PR.com/ 68 69 PR.com provides press release distribution, and is a unique directory of businesses, products and services. Find full company profiles. https://www.pr.com/press-release/971681 Fri, 26 Jun 2026 06:00:00 -0400 Clinical Study Demonstrates Superior Left Ventricular Opacification and Significantly Reduced Acoustic Shadowing Compared with Definity®. [PR.com] https://www.pr.com/press-release/971681 Microvascular Therapeutics, Inc. https://www.pr.com/press-release/952416 Tue, 04 Nov 2025 10:23:16 -0500 Microvascular Therapeutics, Inc. (MVT) today announced the publication of compelling preclinical data demonstrating that its proprietary phase‑shift microbubble platform, MVT‑101 (Solv), significantly enhances sonothrombolysis in a clinically relevant porcine model of deep vein thrombosis (DVT). The study appears in the peer‑reviewed journal Nanotheranostics (Vol. 9, Issue 3, 2025). [PR.com] https://www.pr.com/press-release/952416 Microvascular Therapeutics, Inc. https://www.pr.com/press-release/938732 Thu, 15 May 2025 03:00:00 -0400 Microvascular Therapeutics, Inc. (MVT), a biotechnology company, announced that it has completed data analysis of its Phase II trial of its new ultrasound contrast agent, MVT-100, CardiSon, in echocardiography. In this study, 16 subjects received either the predicate agent Perflutren, or CardiSon, and echocardiographic imaging was performed. The echocardiograms were read and scored by three cardiologists blinded to the [PR.com] https://www.pr.com/press-release/938732 Microvascular Therapeutics, Inc. https://www.pr.com/press-release/920295 Fri, 13 Sep 2024 03:00:00 -0400 Microvascular Therapeutics (MVT), a pioneering healthcare research and development company, is pleased to announce the completion of enrollment in MVT’s Phase 2 program using its microbubble product, MVT-100, for endocardial border delineation. This study, An Ascending Dose Comparison of MVT-100 in Healthy Volunteers, details of which can be found in ClinicalTrials.gov: NCT03882359. The initial results of the study [PR.com] https://www.pr.com/press-release/920295 Microvascular Therapeutics, Inc. https://www.pr.com/press-release/905776 Sat, 10 Feb 2024 03:00:00 -0500 Microvascular Therapeutics Inc. (MVT), a clinical-stage biotech company at the forefront of developing the next generation of microbubbles unlocking the therapeutic potential of ultrasound, proudly announces the appointment of Dr Thom Tulip as their new Chief Business Officer. In this pivotal role, Dr Tulip will lead capital raises to propel MVT's cutting-edge technologies into the market. [PR.com] https://www.pr.com/press-release/905776 Microvascular Therapeutics, Inc. https://www.pr.com/press-release/902198 Wed, 13 Dec 2023 03:00:00 -0500 Microvascular Therapeutics (MVT), a clinical stage biopharma pioneering the potential of ultrasound in diagnostics and theranostics, has been selected to join the prestigious H7 Healthcare Accelerator 2023 Cohort, powered by H7 BioCapital. The program is renowned for providing a dynamic platform and comprehensive commercialization services to support the growth of innovative startups in the healthcare sector. Out of over [PR.com] https://www.pr.com/press-release/902198 Microvascular Therapeutics, Inc. https://www.pr.com/press-release/902201 Wed, 13 Dec 2023 03:00:00 -0500 Microvascular Therapeutics, a trailblazing healthcare research and development company, announces a groundbreaking study on the treatment of Microvascular Obstruction (MVO) through sonoreperfusion. The study, led by Dr. John J. Pacella and his team at the Center for Ultrasound Molecular Imaging and Therapeutics, University of Pittsburgh, in collaboration with Microvascular Therapeutics (MVT), Inc., demonstrates the [PR.com] https://www.pr.com/press-release/902201 Microvascular Therapeutics, Inc. https://www.pr.com/press-release/898374 Wed, 18 Oct 2023 08:11:22 -0400 Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, AZ, was recently awarded a $3.98M FY22 Technology/Therapeutic Development – Funding Level 2 grant from the Congressionally Directed Medical Research Programs (CDMRP). Emmanuelle Meuillet, Chief Scientific and Operating Officer at MVT said, “We are thankful to receive this award from the CDMRP. This will significantly [PR.com] https://www.pr.com/press-release/898374 Microvascular Therapeutics, Inc. https://www.pr.com/press-release/873901 Fri, 25 Nov 2022 03:00:00 -0500 Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of David Lim as Director of Finance at MVT. Mr. Lim brings a broad experience with the business development and strategic financing for diagnostic pharmaceuticals across all modalities. “I have been working with the team at MVT since Q4 of 2021, and it has been my privilege to work alongside [PR.com] https://www.pr.com/press-release/873901 Microvascular Therapeutics, Inc. https://www.pr.com/press-release/873902 Fri, 25 Nov 2022 03:00:00 -0500 Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of Marty Rosenberg to the MVT Board of Scientific Advisors. Mr. Rosenberg brings a broad experience with the clinical development and global regulatory approval process for diagnostic pharmaceuticals across all modalities. “I am very happy to join MVT’s Scientific Advisory Board. I [PR.com] https://www.pr.com/press-release/873902 Microvascular Therapeutics, Inc. https://www.pr.com/press-release/873510 Fri, 18 Nov 2022 03:00:00 -0500 Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, AZ, was recently awarded a Phase I Small Business Innovation Research grant from the National Cancer Institute (NCI). Emmanuelle Meuillet, Chief Scientific and Operating Officer at MVT said, “We are thankful to receive these funds from the NCI and are truly excited about the further development of our product in combination [PR.com] https://www.pr.com/press-release/873510 Microvascular Therapeutics, Inc. https://www.pr.com/press-release/859634 Thu, 21 Apr 2022 03:00:00 -0400 Microvascular Therapeutics (MVT), a clinical stage biotechnology company, finalized its manufacturing facility certifications for the GMP production of its first product, MVT-100. [PR.com] https://www.pr.com/press-release/859634 Microvascular Therapeutics, Inc. https://www.pr.com/press-release/858901 Sat, 09 Apr 2022 03:00:00 -0400 MicrovMicrovascular Therapeutics (MVT), a biotechnology company based in Tucson, AZ, was recently awarded a Commercialization Readiness Program grant from the National Institute of Heart, Lung, and Blood Institute (NHLBI). Wyatt Unger, MD, MBA, Chief Medical Officer of MVT said, “We are humble and grateful to receive continuous support from the NHLBI. The funds will help to improve manufacturing of our novel [PR.com] https://www.pr.com/press-release/858901 Microvascular Therapeutics, Inc. https://www.pr.com/press-release/855635 Wed, 23 Feb 2022 03:00:00 -0500 Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of Timothy Healey to the MVT Board of Directors. Mr. Healey bring a global perspective to pharmaceutical launch and commercialization. “I am very pleased and honored to join MVT’s board. Every year, millions of patients benefit from the improved diagnostic accuracy of contrast enhanced [PR.com] https://www.pr.com/press-release/855635 Microvascular Therapeutics, Inc. https://www.pr.com/press-release/854586 Tue, 08 Feb 2022 03:00:00 -0500 ImaRx Investments, LLC, an investment firm based in Tucson, Arizona, has received ISO-7 certification on February 1st for its GMP manufacturing suite. The 1,800 square foot, ISO-5 capable clean room is designed for manufacturing injectable drugs. The facility is the only one of its kind in Southern Arizona. The facility is jointly leased by two Tucson-based biotechnology companies, Microvascular Therapeutics (MVT) and [PR.com] https://www.pr.com/press-release/854586 Microvascular Therapeutics, Inc. https://www.pr.com/press-release/854179 Thu, 03 Feb 2022 03:00:00 -0500 Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of Shiv Kapoor to the MVT Board of Directors. Mr. Kapoor will bring extensive experience in corporate strategy and financing from both biotechnology and finance industries. “I am honored and excited to join MVT’s board. I see theranostics as the next frontier in personalized and [PR.com] https://www.pr.com/press-release/854179 Microvascular Therapeutics, Inc. https://www.pr.com/press-release/840871 Mon, 19 Jul 2021 07:00:00 -0400 Microvascular Therapeutics (MVT) has received funds from the from the National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health for its program to treat cardiovascular disease, which kills more Americans than any other disease. As a leader in fluorocarbon technology, MVT is currently developing Phase Shift Microbubbles (PSMB) for several therapeutic applications. Evan Unger, MD, [PR.com] https://www.pr.com/press-release/840871 Microvascular Therapeutics, Inc. https://www.pr.com/press-release/818208 Mon, 03 Aug 2020 17:29:00 -0400 Microvascular Therapeutics (MVT), a biotechnology company based in Tucson, AZ, was recently awarded a Phase I Small Business Innovation Research grant from the National Institute of Aging (NIA), part of the National Institutes of Health (NIH). Wyatt Unger, MD, MBA, President and CEO of MVT said, “We are excited about this novel therapeutic application of our product. Worldwide, nearly 50 million people have [PR.com] https://www.pr.com/press-release/818208 Microvascular Therapeutics, Inc. https://www.pr.com/press-release/817617 Fri, 31 Jul 2020 15:59:51 -0400 Microvascular Therapeutics (MVT), a biotechnology company based in Tucson, AZ, was recently awarded a Phase I Small Business Innovation Research grant from the National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health. Wyatt Unger, MD, MBA, President and CEO of MVT said, “Microvascular Thrombi, or small blood clots, are often a result of contemporary treatments of heart attack, [PR.com] https://www.pr.com/press-release/817617 Microvascular Therapeutics, Inc.